Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to Be Held on Thursday March 14th at 8:30 Am ET
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to Be Held on Thursday March 14th at 8:30 Am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.
弗吉尼亞州阿什本，2024年3月7日（環球新聞專線）——專注於罕見病和孤兒病的臨床階段專業製藥公司Quoin Pharmicals Ltd.（納斯達克股票代碼：QNRX）（“公司” 或 “Quoin”）今天宣佈，該公司計劃在2024年3月13日星期三收盤後發佈其第四季度和2023年財務業績。
The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024. The call will include a discussion of fourth quarter and 2023 financial results and a corporate update.
該公司將於美國東部時間2024年3月14日星期四上午 8:30 舉辦電話會議和網絡直播。電話會議將包括對第四季度和2023年財務業績的討論以及公司最新情況。
The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).
撥打 1-800-603-0527（國內）或 1-412-317-0688（國際）即可進行實時通話。
The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZmehVyN5
電話會議的直播和存檔網絡直播也將在Quoin Pharmicals網站上的 “投資者” 欄目下或通過以下鏈接播出： https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZmehVyN5
About Quoin Pharmaceuticals Ltd.
關於 Quoin 製藥有限公司
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Quoin Pharmicals Ltd. 是一家臨床階段的專業製藥公司，專注於開發和商業化治療罕見病和孤兒病的治療產品。我們致力於解決患者、他們的家人、社區和護理團隊未得到滿足的醫療需求。Quoin的創新產品線包括四種正在開發的產品，這些產品共同有可能靶向大量罕見和孤兒適應症，包括內瑟頓綜合徵、皮膚脫皮綜合徵、掌足角化病、硬皮病、大皰性表皮鬆解症等。欲了解更多信息，請訪問： www.quoinpharma.com 要麼 領英 用於更新。
For further information, contact:
Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341
欲了解更多信息，請聯繫：
投資者關係
PCG 諮詢
斯蒂芬妮普林斯
sprince@pcgadvisory.com
(646) 863-6341
譯文內容由第三人軟體翻譯。